GIOSTAR

Executive Summary

GIOSTAR (Global Institute of Stem Cell Therapy and Research) is a US-based biotechnology company with over two decades of experience in developing stem cell therapies for degenerative and genetic diseases. Founded in 2001 and headquartered in San Diego, the company operates globally, with significant clinical and research facilities in India. GIOSTAR's pipeline likely includes multiple allogeneic and autologous stem cell candidates targeting indications such as osteoarthritis, neurological disorders, and metabolic diseases. While the company has not disclosed specific financials or stage, its long history and international presence suggest a mature development platform with potential for near-term clinical milestones. The company's conviction is moderate due to the lack of public disclosure and transparent pipeline updates. However, the longevity of the company and its global operational footprint imply ongoing clinical activity. Upcoming catalysts could include data readouts from ongoing trials, regulatory filings in India or the US, and potential partnerships for commercialization. Given the competitive landscape in cell therapy, GIOSTAR's differentiation lies in its focus on scalable manufacturing and broad therapeutic indications.

Upcoming Catalysts (preview)

• Q4 2026Phase II clinical trial data for osteoarthritis stem cell therapy35% success
• Q1 2027FDA IND clearance for a new indication in neurological disorders40% success
• H2 2026Strategic partnership with a major pharmaceutical company for manufacturing or distribution25% success